JOHNSON & JOHNSON

(JNJ)
  Rapporto
Tempo reale stimato Cboe BZX  -  14:26 05/07/2022
179.15 USD   -0.21%
29/06L'unità di Johnson & Johnson ha ottenuto dalla FDA la designazione di terapia innovativa per il talquetamab nel mieloma multiplo.
MT
24/06Janssen, di Johnson & Johnson, riceve l'approvazione del gruppo di esperti dell'Agenzia europea per i medicinali per un farmaco contro la leucemia.
MT
24/06L'unità Janssen di Johnson & Johnson afferma che il comitato dell'EMA sostiene l'approvazione di Imbruvica per il trattamento della leucemia linfocitica cronica
MT
RiassuntoQuotazioniGraficiNotizieRatingCalendarioSocietàFinanzaConsensusRevisioniDerivati 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su JOHNSON & JOHNSON
09:49INDICES: ni Value, ni Growth, Défensif !
01/07DOJ Says J&J Talc Bankruptcy Violates Congressional Mass Tort Rules
01/07Pharmaceutical companies still have the upper hand
30/06FDA bittet Impfstoffhersteller um Anpassung auf Omikron-Sublinien
30/06Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Talquetamab for..
30/06Hywin Holdings, FactSet Launch Global Health Care Index
29/06NHIF, Janssen Kenya Sign MOU to Enhance Prostrate Cancer Drugs Access
29/06Johnson & Johnson Unit Secures FDA's Breakthrough Therapy Designation For Talquetamab i..
29/06Estas empresas respetan el derecho al aborto en EE.UU.
29/06Ces sociétés respectent le droit à l'avortement aux États-Unis
28/06MeiraGTx Sees Positive Data From Phase 1/2 Trial of Botaretigene Sparoparvovec for X-Li..
27/06Janssen Receives Positive CHMP Opinion for IMBRUVICA (ibrutinib) in a Fixed-Duration Co..
24/06Johnson & Johnson's Janssen Receives EU Medicines Agency Panel's Backing for Leukemia D..
24/06J&J: avis favorable de l'UE pour un anti-leucémique
24/06Johnson & Johnson's Unit Janssen Says EMA's Committee Backs Approval of Imbruvica to Tr..
24/06JOHNSON & JOHNSON'S JANSSEN: CHMP Backs Expanded Imbruvica Use in Chronic Lymphocytic Leu..
24/06J&J: confirme son engagement contre les maladies tropicales
23/06JOHNSON & JOHNSON: Renews Commitment to Fight Neglected Tropical Diseases, Investing in B..
22/06Powell's tall order to reassure investors
22/06ANALYST RECOMMENDATIONS: Johnson & Johnson, NatWest, Home Depot, Kraft Heinz, Vodafone...
21/06Le roi des céréales Kellogg annonce sa scission en trois entreprises
21/06TRANSCRIPT: Johnson & Johnson - Special Call
21/06Johnson & Johnson Opens Asia-Pacific Satellite Center for Global Health Discovery in Si..
21/06Johnson & Johnson Opens First Satellite Center for Global Health Discovery in Asia Paci..
21/06Johnson & Johnson Opens First Satellite Center for Global Health Discovery in Asia Paci..
18/06AFRIQUE DU SUD: une "bataille difficile" remportée avec la levée des brevets
17/06Standard & Poor's 500 Enters Bear Market Territory as Fed Pivot to Price Stability Fuel..
16/06Wall Street finit en forte baisse, craint que la Fed n'ait la main trop lourde
16/06TRANSCRIPT: Johnson & Johnson Presents at Goldman Sachs 43rd Annual Global Healthcare Con..
16/06Federal Government Removes Vaccination Requirements For Domestic And Out-Bound Travel
15/06Top Local Changemakers Addressing Health Equity Gaps Across the U.S. Named Johnson & Jo..
15/06Evotec enters a drug discovery collaboration with Janssen
15/06JOHNSON & JOHNSON VISION ON TRACK FO: ACUVUE® OASYS MAX 1-Day
15/06INSIDER SELL: Johnson & Johnson
14/06Evotec, Johnson & Johnson's Unit Janssen Partner to Discover New Drug Candidates
14/06Evotec kooperiert bei Wirkstoffforschung mit Janssen
13/06Valneva risque de ne pas fournir son vaccin à l'Europe
10/06Johnson & Johnson Unit Janssen Says Early Trial Data Shows Positive Results for Teclist..
10/06JOHNSON & JOHNSON: New IMBRUVICA® (ibrutinib) Data in Fixed-Duration Combination Regimen ..
10/06JOHNSON & JOHNSON: Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bisp..
10/06Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
10/06Genmab Seeks $405 Million in New Arbitration With Janssen
10/06Genmab Opens New Arbitration In Daratumumab License Dispute With Janssen
08/06COVID-19 VACCINES: No Sharing Of Know-How
08/06Johnson & Johnson Releases 2021 Health for Humanity Report Highlighting Performance on ..
08/06Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA (erdafitinib..
08/06Royal Philips - Willem Appelo to succeed Sophie Bechu as Philips Chief Operations Offic..
07/06Johnson & Johnson Unit Janssen Says Initial Data From Phase 2 Trial of Balversa Shows R..
07/06Philips Names Willem Appelo COO
06/06Emergent Biosolutions Claims Janssen Pharmaceuticals Breached COVID-19 Vaccine Producti..
06/06SECTOR UPDATE: Health Care Stocks Slip Amid Losses for Biotechs
06/06Emergent Biosolutions Claims Janssen Pharmaceuticals Breached COVID-19 Vaccine Producti..
06/06SECTOR UPDATE: Health Care Stocks Edging Higher This Afternoon
06/06SECTOR UPDATE: Health Care
06/06US Stocks Weakening in Midday Trading but Largely Staying on Positive Ground
06/06Top Midday Gainers
06/06Yumanity Therapeutics Shares Soar on Kineta Deal
06/06J&J Risks Up to $420 Million Liability as Emergent Claims COVID-19 Jab Contract Breach
06/06Wall Street Set for Gains, China Tech ADRs Rise on Signs of Easing Regulatory Pressure
06/06J&J: résultats encourageants dans le myélome multiple
06/06Emergent BioSolutions Says Janssen Has Breached Covid Vaccine Contract
06/06The Janssen Pharmaceutical - Phase 3 SHINE Results Show IMBRUVICA (ibrutinib)-Based Com..
06/06The Janssen Pharmaceutical Companies - Longer-term Data from CARTITUDE-1 Study Demonstr..
06/06The Janssen Pharmaceutical Companies - Updated Data for Janssen's Bispecific Teclistama..
06/06Top Premarket Gainers
06/06Yumanity to Sell Neurosciences Candidates, Merge With Kineta
06/06J&J: données mises à jour sur le teclistamab
06/06JOHNSON & JOHNSON: ETHICON LAUNCHES NEXT GENERATION ECHELON™ 3000 STAPLER DESIGNED ..
06/06Johnson & Johnson agreed to acquire Assets of Wholesale Brokerage & Binding and Managin..
05/06JOHNSON & JOHNSON: Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and..
03/06Johnson & Johnson's Imbruvica Meets Target in Late-Stage Mantle Cell Lymphoma Trial in ..
03/06JOHNSON & JOHNSON: Phase 3 SHINE Results Show IMBRUVICA® (ibrutinib)-Based Combination Re..
02/06Bristol Myers, J&J Arthritis Drugs Cut Covid-19 Deaths in NIH Study
02/06The Janssen Pharmaceutical - New Data Show Patients Treated with First-in-Class TREMFYA..
01/06J&J: nouvelles données positives autour du Tremfya
1  2  3  4  5  6  7  8  9  10Succ.
Pubblicazioni ufficiali
Prossimo evento su JOHNSON & JOHNSON